MARKET

ELOX

ELOX

ELOXX PHARMACEUT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.890
-0.015
-0.52%
Closed 16:04 12/03 EST
OPEN
2.980
PREV CLOSE
2.905
HIGH
3.030
LOW
2.820
VOLUME
28.18K
TURNOVER
--
52 WEEK HIGH
8.16
52 WEEK LOW
1.440
MARKET CAP
116.04M
P/E (TTM)
-2.8909
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, is pleased to announce that Dr. Gregory Williams, Chief Executive Officer of Eloxx, will participate in a fireside chat and host one-on-one meetings with investors at the Piper Sandler 32 Annual Virtual Growth Conference. The fireside chat will be available on the Piper Sandler Conference website to registered attendees on November 23 at 10:00 AM ET to December 3, 2020.
GlobeNewswire · 11/18 16:52
Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
WALTHAM, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, is pleased to announce that Dr. Gregory Williams, Chief Executive Officer of Eloxx, will participate in a fireside chat and host one-on-one meetings with investors at the Piper Sandler 32nd Annual Virtual Growth Conference. The fireside chat will be available on the Piper Sandler Conference website to registered attendees on November 23rd at 10:00 AM ET to December 3, 2020. The Company will host the one-on-one meetings with investors on Tuesday, December 1, 2020, meetings can be requested exclusively via Piper Sandler.A replay of the fireside chat can be accessed under Events and Presentations in the Investors section of our website at https://investors.eloxxpharma.com/events-and-presentations.Eloxx PharmaceuticalsEloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx’s preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides identified based on read-through potential. Eloxx also has preclinical programs focused on kidney diseases including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders. Eloxx is headquartered in Waltham, MA, with operations in Rehovot, Israel and Morristown, NJ. For more information, please visit www.eloxxpharma.com.Forward-Looking Statements This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, including: the development of the Company’s read-through technology; the approval of the Company’s patent applications; the Company’s ability to successfully defend its intellectual property or obtain necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the Company’s ability to obtain applicable regulatory approvals for its current and future product candidates; the acceptance by the market of the Company’s products should they receive regulatory approval; the timing and success of the Company’s preliminary studies, preclinical research, clinical trials, and related regulatory filings; the ability of the Company to consummate additional financings as needed; the impact of global health concerns, such as the COVID-19 global pandemic, on our ability to continue our clinical and preclinical programs and otherwise operate our business effectively; as well as those discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.Contact:Barbara Ryan 203-274-2825barbarar@eloxxpharma.com SOURCE: Eloxx Pharmaceuticals, Inc.
GlobeNewswire · 11/18 16:30
Global Health Sciences Fund (Quark Venture LP and GF Securities) Announces Portfolio Company SQZ Biotechnologies' IPO
VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Quark Venture LP (Quark) and GF Securities are pleased to announce the successful listing of portfolio company, SQZ Biotechnologies (NYSE: SQZ) ("SQZ") on the New York Stock Exchange (NYSE) as of October 30, 2020. This announcement marks Global Health Sciences (GHS) Fund's third portfolio company to successfully go public after Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) in April 2018 and Keros Therapeutics, Inc. (NASDAQ: KROS) in April 2020.
Globe Newswire · 11/09 13:00
Eloxx Pharmaceuticals Reports Third Quarter 2020 Financial and Operating Results and Provides Business Update
Expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of 2021
GlobeNewswire · 11/05 21:02
Eloxx Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Eloxx Pharmaceuticals, Inc.
ACCESSWIRE · 11/05 19:30
Eloxx Announces The Publication Of Two Manuscripts On ELX-02 And Its ERSG Library In Two Leading Journals
Eloxx Announces The Publication of Two Manuscripts on ELX-02 and It's ERSG Library In Two Leading Journals A Publication titled: "ELX-02: an investigational read-through agent for the treatment of nonsense
Benzinga · 10/27 11:50
Eloxx Announces The Publication of Two Manuscripts on ELX-02 and It's ERSG Library In Two Leading Journals
A Publication titled: "ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease" has been published in the Expert Opinion on Investigational Drugs Journal
GlobeNewswire · 10/27 11:30
Eloxx Presents Two Preclinical Posters at the 2020 North American Cystic Fibrosis Virtual Conference
Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that it presented data from two scientific abstracts at the North American Cystic Fibrosis Virtual Conference (NACFC). The two abstracts were also showcased in the NACFC virtual poster gallery and electronically published as a supplement to Pediatric Pulmonology. The live sessions and discussions will take place through October 23, 2020. These virtual posters are available to registered attendees on the NACFC online conference platform.
GlobeNewswire · 10/22 12:57
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ELOX. Analyze the recent business situations of ELOXX PHARMACEUT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ELOX stock price target is 5.00 with a high estimate of 6.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 68
Institutional Holdings: 10.03M
% Owned: 24.98%
Shares Outstanding: 40.15M
TypeInstitutionsShares
Increased
7
71.10K
New
4
34.42K
Decreased
17
183.22K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.41%
Pharmaceuticals & Medical Research
+0.49%
Key Executives
Chairman/Independent Director
Tomer Kariv
Chief Executive Officer/Director
Gregory Williams
Chief Operating Officer/General Counsel/Secretary
Neil Belloff
Chief Accounting Officer/Vice President - Finance/Treasurer
Stephen MacDonald
Director
Silvia Noiman
Independent Director
Zafrira Avnur
Independent Director
Martijn Kleijwegt
Independent Director
Ran Nussbaum
Independent Director
Steven Rubin
Independent Director
Jasbir Seehra
Independent Director
Gadi Veinrib
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ELOX
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing ribonucleic acid (RNA)-modulating drug candidates, which are designed to be eukaryotic ribosomal selective glycosides (ERSG). It is developing its drug candidates for treating rare and ultra-rare premature stop codon diseases. ELX-02 is its lead investigational drug product candidate. ELX-02 is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis. Its preclinical candidate pool consists of a library of novel ERSG drug candidates identified based on read-through potential and cytoplasmic ribosomal selectivity.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Eloxx Pharmaceuticals Inc stock information, including NASDAQ:ELOX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELOX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ELOX stock methods without spending real money on the virtual paper trading platform.